§ 01 Overview
Overview
Fixed combination of cagrilintide (amylin analog) and semaglutide, studied for additive weight loss in obesity and T2D.
REDEFINE Phase III program reported ~20–22% weight loss. Results fell short of some investor expectations.
§ 02 Mechanism
Mechanism of action
CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). The two mechanisms produce additive appetite suppression and gastric emptying delay.
- 01Additive weight loss vs. either monotherapy
- 02Improved metabolic markers
- 03Preserved lean mass in some trials
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- Combined vial
- BAC Water
- As per product
- Dose Range
- 2 – 6 mg weekly (cagri + sema)
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate to target over several months.
§ 04 Evidence
Evidence & research
REDEFINE Phase III program reported ~20–22% weight loss. Results fell short of some investor expectations.
FDA Status
Investigational. Expected FDA filing late 2025 / 2026.
§ 05 Stacks
Common stacks
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Novo's CagriSema shows 25% weight loss in women, sparking hope for stock recovery. - Pluang
Novo's CagriSema shows 25% weight loss in women, sparking hope for stock recovery. Pluang
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss - The Globe and Mail
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss The Globe and Mail
Weight-Loss Shots Hit Harder in Women. Novo Just Made That Its Pitch - Business Model Analyst
Weight-Loss Shots Hit Harder in Women. Novo Just Made That Its Pitch Business Model Analyst
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients - BioSpace
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients BioSpace
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - Yahoo Finance
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? Yahoo Finance
CagriSema helps women lose 25% of their weight in study - pharmaphorum
CagriSema helps women lose 25% of their weight in study pharmaphorum
Novo Nordisk’s CagriSema delivers 25% average weight loss in women - MedWatch
Novo Nordisk’s CagriSema delivers 25% average weight loss in women MedWatch
Women Lost 25% of Body Weight on CagriSema in Trial Analysis, but Most Users Had Digestive Side Effects - Medical Daily
Women Lost 25% of Body Weight on CagriSema in Trial Analysis, but Most Users Had Digestive Side Effects Medical Daily
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea can be more pronounced than either monotherapy
Contraindications
None specified.
§ 10 Questions
CagriSema FAQ
- What is CagriSema?
- Fixed combination of cagrilintide (amylin analog) and semaglutide, studied for additive weight loss in obesity and T2D. CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). The two mechanisms produce additive appetite suppression and gastric emptying delay.
- What is CagriSema used for?
- Reported uses include additive weight loss vs. either monotherapy, improved metabolic markers, and preserved lean mass in some trials. Evidence strength is rated Clinical — see the evidence section for detail.
- How is CagriSema dosed?
- Commonly referenced dosing is 2 – 6 mg weekly (cagri + sema), administered SubQ. This is educational reference only; consult a licensed clinician before use.
- How do you reconstitute CagriSema?
- For CagriSema, vials commonly come in Combined vial and a common reconstitution is As per product. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
- What are the side effects of CagriSema?
- Commonly reported side effects include nausea can be more pronounced than either monotherapy. This list is not exhaustive.
- Is CagriSema legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Investigational. Expected FDA filing late 2025 / 2026..